Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
August 20, 2024 11:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate...
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
August 19, 2024 17:10 ET
|
Emergent BioSolutions
Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission50,000 doses of ACAM2000®, (Smallpox...
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
August 06, 2024 17:01 ET
|
Emergent BioSolutions
Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) millionUpdates FY 2024 guidance ...
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
August 06, 2024 08:00 ET
|
Emergent BioSolutions
Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE)...
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
July 31, 2024 08:53 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a...
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
July 24, 2024 07:30 ET
|
Emergent BioSolutions
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE...
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
July 23, 2024 08:27 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions annonce la prolongation de la durée de vie du vaporisateur nasal NARCAN® au Canada
July 22, 2024 08:00 ET
|
Emergent Biosolutions, Inc.
Le fait de porter à quatre ans la durée de vie du vaporisateur nasal NARCAN® contribue à améliorer l’accès à la naloxone dans un contexte où les communautés sont toujours aux prises avec une hausse...
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
July 22, 2024 08:00 ET
|
Emergent BioSolutions
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
July 09, 2024 07:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash...